|
Modulating the AIBP-CAV1-VEGFR3 axis to treat lymphatic disorders
This invention is a method of promoting lymphangiogenesis in order to treat lymphatic disorders, namely lymphedema and Alzheimer’s disease (AD). VEGFC-induced VEGFR3 signaling is the major driver of lymphangiogenesis, however the distinct molecular mechanisms determining how VEGFR3 signaling controls lymphatic endothelial cell (LEC) fate remains...
Published: 3/12/2024
|
Inventor(s): Longhou Fang, Jun-dae Kim
Keywords(s):
Category(s): Clinical Area > Metabolic Disease, Inflammation, and Immunology, Clinical Area > Neurology, Clinical Area > Cardiovascular, Research Area > Heart and Vascular, Research Area > Immunobiology and Inflammation, Research Area > Neurology and Neurosurgery, Technology Classifications > Therapeutic > Cell and Gene Therapies, Technology Classifications > Therapeutic > Small Molecules, Technology Classifications > Therapeutic > Biologics
|
|
Beclin 2-Functionalized Therapies for Treatment of Neurodegenerative Disease and Cancer
This invention identified that Beclin 2 functions as a negative regulator of the ERK1/2 signaling, NF-κB signaling, and inflammasome activation. Furthermore, these studies demonstrated that Beclin 2 targets key signalling kinases for degradation through an ATG9A-dependent autophagic pathway. These new findings have uncovered an important role...
Published: 3/25/2024
|
Inventor(s): Rongfu Wang, Helen (Yicheng) Wang, Motao Zhu
Keywords(s):
Category(s): Clinical Area > Cancer, Clinical Area > Neurology, Research Area > Cancer, Research Area > Immunobiology and Inflammation, Research Area > Neurology and Neurosurgery, Technology Classifications > Therapeutic > Biologics, Technology Classifications > Therapeutic > Small Molecules, Technology Classifications > Therapeutic > Immunotherapy
|
|
Glycolytic Modulators for Therapeutic Regulation of Cell Fate
This invention is a glycolysis enhancement strategy using glycolytic modulators to improve cell fate transitions. Applied topically, systemically, or in combination with a biocompatible scaffold, the glycolytic enhancers are expected to improve wound healing, vascularity, and tissue regeneration as well as reduce fibrosis. In another application, a...
Published: 3/12/2024
|
Inventor(s): John Cooke, Li Lai
Keywords(s):
Category(s): Technology Classifications > Therapeutic > Small Molecules, Research Area > Regenerative Medicine, Clinical Area > Cancer, Research Area > Cancer
|
|
SREBP2 Inhibitors for Treating T-Cell Acute Lymphoblastic Leukemia
This invention is a method of inhibiting sterol regulatory element-binding protein 2 (SREBP2) in order to treat, prevent, reverse, and/or ameliorate conditions associated with an improper number of hematopoietic stem and progenitor cells (HSPCs). SREBP22 is traditionally known as a transcription factor that plays a role in cholesterol homeostasis. However,...
Published: 3/12/2024
|
Inventor(s): Longhou Fang, Qilin Gu
Keywords(s):
Category(s): Technology Classifications > Therapeutic > Small Molecules, Technology Classifications > Therapeutic > Cell and Gene Therapies, Clinical Area > Cancer, Research Area > Cancer
|
